When So Much Depends on So Much: Optimizing Data Integration in the Bioinformatics Community
Innovation is the life blood of the pharmaceutical industry, and innovation runs on data. However, it is not only a company’s access to quality data, but also what an organization does with that data that determines its potential for success. Fewer and fewer problems in the globally competitive marketplace today can be answered with just a single category or class of content. It is no longer enough to run queries across an isolated target database or drug data bank.Because so much depends on so much, data integration is now more important than ever to sustaining a trim and efficient organization. Most Pharma companies know they are sitting on unique data assets that can be used to discover new insights, repurpose previously failed drug programs, or revisit trial results to identify new segments. However, because the cornucopia of open and public data banks available today is staggering, many organizations don’t quite know how to fit external data sources into their workflows alongside data generated internally. Data integration is an area that Thomson Reuters has supported clients with for many years. Our own experience connecting data for our databases, combined with the ontologies we’ve built up for that purpose, prove very useful in helping customers “connect the dots” and get all these data into a format that supports informatics techniques. I recently participated in a podcast “Optimizing data integration for your scientific discovery” discussing recent trends in bioinformatics, novel data integration practices implemented by our clients in genome sequencing and clinical trials, in addition to best practices in the use of APIs, dashboards, and predictive models. We will also be discussing the importance of data integration in life sciences at the 2016 BioIT World Conference being held in Boston this April, and invite you to join Tim Miller, Thomson Reuters VP Platform Architecture, for his presentation “Why is Data Integration So Hard?” Additionally, we will showcase a new scientific poster, “Molecular Profiles of Tumor Infiltrating T-lymphocytes in Breast Cancer Patients.” For questions about Thomson Reuters’ depth and breadth of life sciences curated content, please join us at Booth #157.